Drug intelligence / Profile preview

AdC6-HIVgp140

Development stage: Phase 1
Lead developer: HIV Vaccine Trials Network
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AdC6-HIVgp140 is a chimpanzee-derived replication-defective adenovirus (Ad) vector expressing codon optimized gp140 of clade C isolate Du422. It is being developed as an HIV-1 vaccine candidate that aims to induce immune responses against HIV envelope proteins. The vaccine is administered intramuscularly and is being tested in various prime-boost regimens, including combinations with AdC7-HIVgp140 and protein boosts like CH505TF gp120 adjuvanted with GLA-SE.

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on AdC6-HIVgp140.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdC6-HIVgp140.

Explore the full profile